Kyntra Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
Completed restructuring of royalty financing agreement, reducing the maximum aggregate payment obligation by $60 million, with only $15 million in future royalty-backed payments remaining Initiation of the pivotal Phase 3 trial of roxadustat for the …